PDCD1 and cancer: Marked improvement in clinical outcome had been achieved by checkpoint blockers targeting programmed death-1/programmed death ligand-1 (PD-1/PD-L1) in a wide spectrum of cancer entities including non-small cell lung cancer (NSCLC), melanoma etc. [11, 12].